The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Single institution experience with peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET).
 
Heying Duan
No Relationships to Disclose
 
Gaia Ninatti
No Relationships to Disclose
 
Bradley Girod
No Relationships to Disclose
 
Valentina Ferri
No Relationships to Disclose
 
Pamela L. Kunz
Stock and Other Ownership Interests - Guardant Health; Guardant Health; Guardant Health; Guardant Health
Consulting or Advisory Role - Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; Ipsen; Ipsen; Ipsen; Ipsen; Lexicon; Lexicon; Lexicon; Lexicon; Novartis; Novartis; Novartis; Novartis
Research Funding - Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); Brahms (Inst); Brahms (Inst); Brahms (Inst); Brahms (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Lexicon (Inst); Lexicon (Inst); Lexicon (Inst); Lexicon (Inst); Xencor (Inst); Xencor (Inst); Xencor (Inst); Xencor (Inst)
 
George A. Fisher
Stock and Other Ownership Interests - Seagen (I); Seagen (I); Seagen (I); Seagen (I)
Honoraria - Aduro Biotech; Aduro Biotech; Aduro Biotech; Aduro Biotech; Forty Seven; Forty Seven; Forty Seven; Forty Seven; Genentech; Genentech; Genentech; Genentech; Incyte; Incyte; Incyte; Incyte; Merck; Merck; Merck; Merck; Newlink Genetics; Newlink Genetics; Newlink Genetics; Newlink Genetics
Consulting or Advisory Role - Aduro Biotech; Aduro Biotech; Aduro Biotech; Aduro Biotech; Forty Seven; Forty Seven; Forty Seven; Forty Seven; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Incyte; Incyte; Incyte; Incyte; ipsen; ipsen; ipsen; ipsen; Jounce Therapeutics; Jounce Therapeutics; Jounce Therapeutics; Jounce Therapeutics; Merck; Merck; Merck; Merck; Newlink Genetics; Newlink Genetics; Newlink Genetics; Newlink Genetics
Research Funding - Aduro Biotech (Inst); Aduro Biotech (Inst); Aduro Biotech (Inst); Aduro Biotech (Inst); Forty seven (Inst); Forty seven (Inst); Forty seven (Inst); Forty seven (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme
 
Farshad Moradi
No Relationships to Disclose
 
Guido Alejandro Davidzon
No Relationships to Disclose
 
Benjamin Lewis Franc
No Relationships to Disclose
 
Andrei Iagaru
Consulting or Advisory Role - Isotopen Technologien; Isotopen Technologien; Isotopen Technologien; Isotopen Technologien
Research Funding - Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); GE Healthcare (Inst); GE Healthcare (Inst); GE Healthcare (Inst); GE Healthcare (Inst); Progenics (Inst); Progenics (Inst); Progenics (Inst); Progenics (Inst)
Travel, Accommodations, Expenses - GE Healthcare; GE Healthcare; GE Healthcare; GE Healthcare
 
Carina Mari
No Relationships to Disclose